Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Microwave Ablation Guided by Computed Tomography for T1a Renal Cell Carcinoma: A Comparative Analysis with Robot-Assisted Laparoscopic Partial Nephrectomy

  • By

  • Rasmus D. Petersson

  • Thomas Bretlau

  • Munkith Abbas

  • Katrine S. Schou-Jensen

  • Frederik F. Thomsen

  • November 17, 2025

Share

  • 1

    Partial nephrectomy is the preferred treatment for localized renal cell carcinoma due to better renal function preservation compared to radical nephrectomy.

  • 2

    Robot-assisted laparoscopic partial nephrectomy is associated with lower morbidity and shorter hospital stays compared to open partial nephrectomy.

  • 3

    Microwave ablation is a viable alternative for patients unfit for major surgery, showing effectiveness comparable to other ablation therapies.

  • 4

    The study compared safety and oncological outcomes of microwave ablation and robot-assisted laparoscopic partial nephrectomy for clinical T1a RCC.

  • 5

    Patients undergoing microwave ablation had higher comorbidity scores and worse kidney function compared to those undergoing robot-assisted laparoscopic partial nephrectomy.

Original Source(s)

Computed tomography guided microwave ablation for the treatment of clinical T1a renal cell carcinoma: a comparison to robot-assisted laparoscopic partial nephrectomy

  • by Rasmus D. Petersson, Thomas Bretlau, Munkith Abbas, Katrine S. Schou-Jensen, Frederik F. Thomsen

  • November 17, 2025

Related Content

Race, ethnicity, and language are underreported in hip fracture CPGs

Experts Call for Risk-Based Periodontal Prevention

New recommendations emphasize individualized use of adjunctive antiseptics when mechanical biofilm control alone may be insufficient.

FDA approves gene therapy for MPS IIIA

The one-time intravenous treatment uses adeno-associated virus serotype 9 to deliver a functional copy of the SGSH gene.